Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...
Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...
Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it ...
Hims & Hers (NYSE: HIMS) is taking investors on a roller-coaster ride in 2025. Where to invest $1,000 right now? Our analyst ...
Hims & Hers Health ( HIMS -12.56%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...
Hims & Hers Health ( HIMS -15.90%) has been a top healthcare stock to own over the past five years, soaring by around 350% ...
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...
Hims & Hers Health, Inc. (NYSE:HIMS) stock is trading lower on Wednesday, with a session volume of 7.7 million compared to ...
In other words, while Hims & Hers' tirzepatide business is going away ... On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they ...
Hims & Hers Health (NYSE: HIMS) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some (vicariously) bad news out of the Great State of Texas. The U.S. District Court for ...
For investors and stakeholders in Hims & Hers, the FDA's decision offers some regulatory certainty in the near term. The company's stock performance will continue to be influenced by its ability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results